HRP20110294T1 - Smjese u obliku tablete koje sadržavaju atazanavir - Google Patents
Smjese u obliku tablete koje sadržavaju atazanavir Download PDFInfo
- Publication number
- HRP20110294T1 HRP20110294T1 HR20110294T HRP20110294T HRP20110294T1 HR P20110294 T1 HRP20110294 T1 HR P20110294T1 HR 20110294 T HR20110294 T HR 20110294T HR P20110294 T HRP20110294 T HR P20110294T HR P20110294 T1 HRP20110294 T1 HR P20110294T1
- Authority
- HR
- Croatia
- Prior art keywords
- compressed tablet
- tablet according
- relation
- total weight
- lubricant
- Prior art date
Links
- 108010019625 Atazanavir Sulfate Proteins 0.000 title claims abstract 8
- 239000000203 mixture Substances 0.000 title claims abstract 3
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 title 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 title 1
- 229960003277 atazanavir Drugs 0.000 title 1
- 239000007891 compressed tablet Substances 0.000 claims abstract 20
- 239000000314 lubricant Substances 0.000 claims abstract 9
- YSIBYEBNVMDAPN-CMDGGOBGSA-N (e)-4-oxo-4-(3-triethoxysilylpropylamino)but-2-enoic acid Chemical compound CCO[Si](OCC)(OCC)CCCNC(=O)\C=C\C(O)=O YSIBYEBNVMDAPN-CMDGGOBGSA-N 0.000 claims abstract 7
- 229960003796 atazanavir sulfate Drugs 0.000 claims abstract 7
- 239000008187 granular material Substances 0.000 claims abstract 7
- 239000003826 tablet Substances 0.000 claims abstract 5
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 5
- 229960000311 ritonavir Drugs 0.000 claims 5
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 238000005550 wet granulation Methods 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims 1
- 239000008116 calcium stearate Substances 0.000 claims 1
- 235000013539 calcium stearate Nutrition 0.000 claims 1
- 239000004203 carnauba wax Substances 0.000 claims 1
- 235000013869 carnauba wax Nutrition 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 235000019438 castor oil Nutrition 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
- 229940075507 glyceryl monostearate Drugs 0.000 claims 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000002480 mineral oil Substances 0.000 claims 1
- 235000010446 mineral oil Nutrition 0.000 claims 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims 1
- 235000010234 sodium benzoate Nutrition 0.000 claims 1
- 239000004299 sodium benzoate Substances 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 abstract 1
- 229940124411 anti-hiv antiviral agent Drugs 0.000 abstract 1
- -1 e.g. Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94569407P | 2007-06-22 | 2007-06-22 | |
PCT/US2008/067633 WO2009002829A2 (en) | 2007-06-22 | 2008-06-20 | Tableted compositions containing atazanavir |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20110294T1 true HRP20110294T1 (hr) | 2011-05-31 |
Family
ID=39645403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20110294T HRP20110294T1 (hr) | 2007-06-22 | 2011-04-21 | Smjese u obliku tablete koje sadržavaju atazanavir |
Country Status (17)
Country | Link |
---|---|
US (2) | US20100183716A1 (es) |
EP (1) | EP2178513B1 (es) |
JP (1) | JP2010530892A (es) |
KR (1) | KR20100033377A (es) |
CN (1) | CN101795674A (es) |
AT (1) | ATE503467T1 (es) |
AU (1) | AU2008268537B2 (es) |
CY (1) | CY1111957T1 (es) |
DE (1) | DE602008005896D1 (es) |
DK (1) | DK2178513T3 (es) |
ES (1) | ES2361796T3 (es) |
HR (1) | HRP20110294T1 (es) |
MX (1) | MX2009013461A (es) |
PL (1) | PL2178513T3 (es) |
PT (1) | PT2178513E (es) |
SI (1) | SI2178513T1 (es) |
WO (1) | WO2009002829A2 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2009013499A (es) * | 2007-06-22 | 2010-01-18 | Bristol Myers Squibb Co | Composiciones comprimidas que contienen atazanavir. |
CA2703918C (en) * | 2007-10-29 | 2016-10-18 | Cipla Limited | Solid pharmaceutical dosage forms of atazanavir and ritonavir combinations |
EP2399921B1 (en) | 2008-12-01 | 2015-08-12 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
US10071059B2 (en) * | 2009-12-18 | 2018-09-11 | Frieslandcampina Nederland Holding B.V. | Co-processed tablet excipient composition its preparation and use |
JP6158702B2 (ja) | 2010-04-09 | 2017-07-05 | ブリストル−マイヤーズ・スクイブ・ホールディングス・アイルランドBristol−Myers Squibb Holdings Ireland | pHの影響を改善したアタザナビル硫酸塩製剤 |
CN104884063A (zh) | 2012-10-23 | 2015-09-02 | 西普拉有限公司 | 抗逆转录病毒药物组合物 |
WO2015028875A2 (en) * | 2013-08-29 | 2015-03-05 | Teva Pharmaceuticals Industries Ltd. | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir |
CN104784133A (zh) * | 2014-01-19 | 2015-07-22 | 广东东阳光药业有限公司 | 一种齐多夫定的片剂及其制备方法 |
KR101669240B1 (ko) * | 2015-03-12 | 2016-10-25 | 아주대학교산학협력단 | 테노포비어 디소프록실 유리염기를 포함하는 정제 및 이의 제조방법 |
CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
GB201800249D0 (en) * | 2018-01-08 | 2018-02-21 | Univ Of Sussex | Pickering emulsions |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2940998A (en) * | 1953-10-15 | 1960-06-14 | Ajinomoto Kk | Process for resolution of racemic glutamic acid and salts thereof |
GB919491A (en) * | 1958-12-23 | 1963-02-27 | Ici Ltd | Pharmaceutical compositions |
US4026897A (en) * | 1974-01-31 | 1977-05-31 | Otsuka Pharmaceutical Company | 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives |
US3980637A (en) * | 1975-03-17 | 1976-09-14 | Bristol-Myers Company | Production of amoxicillin |
US4556654A (en) * | 1983-06-28 | 1985-12-03 | Warner-Lambert Company | Antimicrobial substituted anthra[1,9-cd]pyrazol-6(2H)-ones |
DE3403329A1 (de) * | 1984-02-01 | 1985-08-01 | Horst Dr. 4019 Monheim Zerbe | Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe |
FR2623810B2 (fr) * | 1987-02-17 | 1992-01-24 | Sanofi Sa | Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant |
US5158777A (en) * | 1990-02-16 | 1992-10-27 | E. R. Squibb & Sons, Inc. | Captopril formulation providing increased duration of activity |
CA2068402C (en) * | 1991-06-14 | 1998-09-22 | Michael R. Hoy | Taste mask coatings for preparation of chewable pharmaceutical tablets |
US5753652A (en) * | 1991-07-03 | 1998-05-19 | Novartis Corporation | Antiretroviral hydrazine derivatives |
CA2103932A1 (en) * | 1992-11-05 | 1994-05-06 | Ramesh N. Patel | Stereoselective reduction of ketones |
US5461067A (en) * | 1993-02-25 | 1995-10-24 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5428048A (en) * | 1993-11-08 | 1995-06-27 | American Home Products Corporation | Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents |
GB9407386D0 (en) * | 1994-04-14 | 1994-06-08 | Smithkline Beecham Plc | Pharmaceutical formulation |
UA49803C2 (uk) * | 1994-06-03 | 2002-10-15 | Дж.Д. Сьорль Енд Ко | Спосіб лікування ретровірусних інфекцій |
TW483763B (en) * | 1994-09-02 | 2002-04-21 | Astra Ab | Pharmaceutical composition comprising of ramipril and dihydropyridine compound |
JP3529904B2 (ja) * | 1995-06-19 | 2004-05-24 | 鐘淵化学工業株式会社 | 光学活性1−ハロ−3−アミノ−4−フェニル−2−ブタノール誘導体の製造法 |
US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
US5750493A (en) * | 1995-08-30 | 1998-05-12 | Raymond F. Schinazi | Method to improve the biological and antiviral activity of protease inhibitors |
CA2190570C (en) * | 1995-11-17 | 2005-05-03 | Yutaka Honda | Process for producing 3-amino-2-oxo-1-halogenopropane derivatives |
US5849911A (en) * | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
US6087383A (en) * | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
AU3075400A (en) * | 1999-01-21 | 2000-08-07 | Kaneka Corporation | Method for purifying and isolating (2s,3s)- or (2r,3s)-halohydrin derivatives |
EP1661893A3 (en) * | 1999-01-29 | 2006-06-07 | Kaneka Corporation | Process for the preparation of threo-1,2-epoxy-3-amino-4-phenylbutane derivatives |
EP1165521A4 (en) * | 1999-03-22 | 2002-05-22 | Bristol Myers Squibb Co | FUSED COMPOUNDS OF PYRIDOPYRIDAZINE CGMP PHOSPHODIESTERASE INHIBITORS |
US6605732B1 (en) * | 1999-05-03 | 2003-08-12 | Aerojet Fine Chemicals Llc | Clean, high-yield preparation of S,S and R,S amino acid isosteres |
KR100708221B1 (ko) * | 1999-08-31 | 2007-04-17 | 아지노모토 가부시키가이샤 | 에폭사이드 결정의 제조방법 |
US6399393B1 (en) * | 1999-09-21 | 2002-06-04 | The United States Of America As Represented By The Department Of Energy | Cryogenic homogenization and sampling of heterogeneous multi-phase feedstock |
US6414002B1 (en) * | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
US6254888B1 (en) * | 2000-01-28 | 2001-07-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for coating pharmaceutical dosage forms |
US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
YU34501A (sh) * | 2000-05-26 | 2003-10-31 | Pfizer Products Inc. | Postupak reaktivne kristalizacije radi povećanja veličine čestica |
AU2001280698B2 (en) * | 2000-08-16 | 2005-08-25 | Bristol-Myers Squibb Holdings Ireland Unlimited Company | Stereoselective reduction of substituted oxo-butanes |
IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
US6670344B2 (en) * | 2000-09-14 | 2003-12-30 | Bristol-Myers Squibb Company | Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts |
KR20020046948A (ko) * | 2000-12-12 | 2002-06-21 | 에가시라 구니오 | 에폭사이드 결정의 제조방법 |
RU2316341C2 (ru) * | 2001-08-31 | 2008-02-10 | Бристол-Маерс Сквибб Компани | Применение атазанавира в терапии вич-инфекции |
KR100933625B1 (ko) * | 2001-09-04 | 2009-12-24 | 다우 글로벌 테크놀로지스 인크. | 수성 에어 포움, 이를 사용한 고체 입자의 응집방법 및 피복방법 |
US7384734B2 (en) * | 2002-02-15 | 2008-06-10 | Monogram Biosciences, Inc. | Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors |
KR100456833B1 (ko) * | 2002-08-01 | 2004-11-10 | 주식회사 대웅 | 아목시실린 및 클라불라네이트를 함유하는 유핵정 |
FR2855756B1 (fr) * | 2003-06-06 | 2005-08-26 | Ethypharm Sa | Comprime orodispersible multicouche |
US20050148523A1 (en) * | 2003-12-15 | 2005-07-07 | Colonno Richard J. | Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor |
TW200534879A (en) * | 2004-03-25 | 2005-11-01 | Bristol Myers Squibb Co | Coated tablet formulation and method |
US7829720B2 (en) * | 2004-05-04 | 2010-11-09 | Bristol-Myers Squibb Company | Process for preparing atazanavir bisulfate and novel forms |
US20050256314A1 (en) * | 2004-05-04 | 2005-11-17 | Soojin Kim | Process employing controlled crystallization in forming crystals of a pharmaceutical |
US20050288343A1 (en) * | 2004-05-19 | 2005-12-29 | Andrew Rusowicz | Process of preparing substituted carbamates and intermediates thereof |
TWI415635B (zh) * | 2004-05-28 | 2013-11-21 | 必治妥施貴寶公司 | 加衣錠片調製物及製備彼之方法 |
AR045841A1 (es) * | 2004-09-28 | 2005-11-16 | Richmond Sa Com Ind Y Financie | Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla. |
US7582468B2 (en) * | 2005-05-25 | 2009-09-01 | Bristol-Myers Squibb Company | Process for preparing (2R,3S)-1,2-epoxy-3-(protected)amino-4-substituted butane and intermediates thereof |
WO2007013047A2 (en) * | 2005-07-29 | 2007-02-01 | Ranbaxy Laboratories Limited | Water-dispersible anti-retroviral pharmaceutical compositions |
-
2008
- 2008-06-20 AT AT08771569T patent/ATE503467T1/de active
- 2008-06-20 PL PL08771569T patent/PL2178513T3/pl unknown
- 2008-06-20 SI SI200830227T patent/SI2178513T1/sl unknown
- 2008-06-20 WO PCT/US2008/067633 patent/WO2009002829A2/en active Application Filing
- 2008-06-20 ES ES08771569T patent/ES2361796T3/es active Active
- 2008-06-20 JP JP2010513439A patent/JP2010530892A/ja active Pending
- 2008-06-20 AU AU2008268537A patent/AU2008268537B2/en not_active Ceased
- 2008-06-20 EP EP08771569A patent/EP2178513B1/en active Active
- 2008-06-20 PT PT08771569T patent/PT2178513E/pt unknown
- 2008-06-20 KR KR1020097026604A patent/KR20100033377A/ko not_active Application Discontinuation
- 2008-06-20 MX MX2009013461A patent/MX2009013461A/es active IP Right Grant
- 2008-06-20 CN CN200880103484A patent/CN101795674A/zh active Pending
- 2008-06-20 DK DK08771569.4T patent/DK2178513T3/da active
- 2008-06-20 US US12/664,802 patent/US20100183716A1/en not_active Abandoned
- 2008-06-20 DE DE602008005896T patent/DE602008005896D1/de active Active
-
2011
- 2011-04-21 HR HR20110294T patent/HRP20110294T1/hr unknown
- 2011-06-28 CY CY20111100620T patent/CY1111957T1/el unknown
-
2014
- 2014-07-02 US US14/322,478 patent/US20150320731A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2009002829A3 (en) | 2009-11-05 |
AU2008268537B2 (en) | 2012-11-01 |
EP2178513A2 (en) | 2010-04-28 |
PL2178513T3 (pl) | 2011-09-30 |
JP2010530892A (ja) | 2010-09-16 |
MX2009013461A (es) | 2010-01-15 |
DE602008005896D1 (de) | 2011-05-12 |
US20150320731A1 (en) | 2015-11-12 |
AU2008268537A1 (en) | 2008-12-31 |
DK2178513T3 (da) | 2011-07-11 |
EP2178513B1 (en) | 2011-03-30 |
WO2009002829A2 (en) | 2008-12-31 |
ATE503467T1 (de) | 2011-04-15 |
US20100183716A1 (en) | 2010-07-22 |
CY1111957T1 (el) | 2015-11-04 |
SI2178513T1 (sl) | 2011-05-31 |
CN101795674A (zh) | 2010-08-04 |
ES2361796T3 (es) | 2011-06-22 |
KR20100033377A (ko) | 2010-03-29 |
PT2178513E (pt) | 2011-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20110294T1 (hr) | Smjese u obliku tablete koje sadržavaju atazanavir | |
HRP20140146T1 (hr) | Smjese koje sadrže atazanavir oblikovane u tablete | |
JP2010530889A5 (es) | ||
JP2010530892A5 (es) | ||
RS54187B1 (en) | PHARMACEUTICAL COMPOSITIONS WITH CONTROLLED RELEASE CONTAINING FUMARIC ACID ESTAR | |
NZ594589A (en) | 3h-imidazo [4, 5 -c] pyridine- 6 -carboxamides as anti- inflammatory agents | |
JP5812408B2 (ja) | 排泄物処理剤 | |
RS54329B1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING RIFAXIMINE, PROCEDURES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS | |
ECSP055688A (es) | Nuevas formulaciones farmacéuticas sólidas que comprenden telmisartano y su preparación | |
RU2017134002A (ru) | Стабильные композиции тетрагидробиоптерина | |
AR060019A1 (es) | Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo | |
WO2008093075A3 (en) | 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors | |
UA116334C2 (uk) | Тверді форми дозування бендамустину | |
SI2729130T1 (en) | Combined formulations of darunavir | |
BRPI0513598A (pt) | formas de dosagem em comprimidos revestidos de liberação entérica | |
JP2010530890A5 (es) | ||
BR112022011295A2 (pt) | Forma de dosagem para uso no tratamento ou na prevenção de uma doença | |
HRP20191217T1 (hr) | Čvrsti farmaceutski sastav citizina i postupak pripreme istog | |
JP6213982B2 (ja) | 塊状処理剤 | |
BR0313651A2 (pt) | composiÇço para administraÇço oral ou rectal | |
NZ611026A (en) | Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria | |
SI2676657T1 (en) | A composition for treating hypocalcaemia in ruminants | |
MX2023001014A (es) | Composiciones farmaceuticas que comprenden venglustat. | |
HRP20240236T1 (hr) | Pripravci i njihova upotreba | |
CN101601386A (zh) | 一种含氟菌唑与百菌清的杀菌组合物 |